Trial Profile

A Phase III study of PTI-428, PTI-808 and PTI-801 combination

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dirocaftor (Primary) ; Nesolicaftor (Primary) ; Posenacaftor (Primary) ; PTI NC 733 (Primary)
Indications Cystic fibrosis
Focus Registrational; Therapeutic Use
Acronyms MORE
Sponsors Kineta; Proteostasis Therapeutics; TuHURA Biosciences; Yumanity Therapeutics

Most Recent Events

30 Jun 2025 According to TuHURA Biosciences media release, Kineta has been acquired and merged into TuHURA Biosciences.
19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
13 Jan 2020 According to a Proteostasis Therapeutics media release, the company completed a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com